Physician profile
Robert J Boolbol
NPI 1316935034
$15,455.55
in general payments reported to CMS, 2019-2025
51 companies · $1,799 in 2025
The $1,799 reported for 2025 was more than what 76% of Interventional Pain Medicine providers received nationally (typical 2025 total: $676).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,197 · 2020: $1,690 · 2021: $2,687 · 2022: $2,509 · 2023: $2,340 · 2024: $2,235 · 2025: $1,799.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,373.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,372.92 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Scilex Pharmaceuticals INC. | $2,685.51 | 2019-2025 | Ztlido |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $2,478.01 | 2019-2025 | Relistor |
| Collegium Pharmaceutical, INC. | $1,937.46 | 2019-2025 | Xtampza |
| Abbvie INC. | $1,247.22 | 2021-2025 | Ubrelvy, Qulipta |
| Takeda Pharmaceuticals U.S.A., INC. | $1,132.25 | 2019-2025 | Trintellix |
| Pfizer INC. | $610.11 | 2019-2025 | |
| Tersera Therapeutics LLC | $574.58 | 2019-2025 | Prialt |
| Redhill Biopharma INC. | $561.41 | 2020-2022 | |
| Ibsa Pharma INC. | $451.94 | 2020-2024 | Tirosint, Licart, Licart |
| Arbor Pharmaceuticals, INC. | $443.35 | 2019-2021 | |
| Idorsia Pharmaceuticals US INC | $372.72 | 2022-2024 | Quviviq |
| Daiichi Sankyo INC. | $207.16 | 2019 | |
| Nevro Corp. | $156.30 | 2019-2020 | |
| Biohaven Pharmaceutical Holding Company LTD. | $150.46 | 2022 | |
| Mdd US Operations, LLC | $150.36 | 2019-2020 |
Show all 51 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Boolbol listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.